

# Programme EACPT 2017

## Saturday, 24 June

9:00 to 12:30  
Room Meridian

### YOUNG CLINICAL PHARMACOLOGISTS SESSION

#### 1st part: Metaanalysis and systematic review

##### **Speakers:**

Matthieu Roustit, *University Grenoble Alpes, France*

Joaquín Sáez-Peñataro, *Hospital Clínic Barcelona, Spain*

#### 2nd part: Oral presentations and discussion

##### **CYP4F2 GENOTYPE AFFECTS CIRCULATING PLASMA VITAMIN K CONCENTRATION IN CHILDREN ON CHRONIC WARFARIN THERAPY**

Emmanouela Kampouraki<sup>1</sup>, Peter Avery<sup>2</sup>, Tina Biss<sup>3</sup>, Farhad Kamali<sup>1</sup>

*Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK*

*School of Mathematics & Statistics, Newcastle University, Newcastle upon Tyne, UK*

*Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne, UK*

##### **INHIBITORY INTERACTION POTENTIAL OF LINEZOLID ON SOLUTE CARRIER FAMILY (SLCO)-1B1 and-1B3 TRANSPORTERS MEDIATED RIFAMPIN UPTAKE, IN VITRO**

N Kaisar<sup>1</sup>, MM Parvez<sup>1</sup>, YJ Lee<sup>1</sup>, HJ Shin<sup>1</sup>, JA Jung<sup>2</sup>, J-G Shin<sup>1,2</sup>

*Inje University College of Medicine, South Korea*

*Inje University Busan Paik Hospital, Busan, South Korea*

##### **SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE AND MULTIPLE DOSE JPI-289, A NOVEL POLY (ADP-RIBOSE) POLYMERASE-1 INHIBITOR IN FIRST-IN-HUMAN STUDY OF HEALTHY VOLUNTEERS**

Sungpil Han<sup>1</sup>, Yo Han Kim<sup>1</sup>, Hee Youn Choi<sup>1</sup>, Dong-Jun Soh<sup>2</sup>, Jung-Min Kim<sup>2</sup>,

Joon-Woo Nam<sup>2</sup>, Jong-Woo Kim<sup>2</sup>, Kyun-Seop Bae<sup>1</sup>, Hyeong-Seok Lim<sup>1</sup>

*College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Republic of Korea*

*Jeil Pharmaceutical Co., Ltd., Seoul, Republic of Korea*

##### **SEPSIS BIOMARKER PROGNOSTIC SIGNIFICANCE – PRESEPSIN ROLE IN REAL CLINICAL PRACTICE**

Mariya Lukina, Mariya Chukina, Tatiana Andruchichina, Tatiana Morozova

*I.M.Sechenov First Moscow State Medical University, Russia*

14:00 to 15:00  
Room Meridian

### WELCOME SESSION AND OPENING CEREMONY

Milan Grundmann (Czech Republic), Tabassome Simon (France), Ylva Böttiger (Sweden)

- Introduction of EACPT and welcome to first-time attendees

Saturday 24 June

- Evolution of the EACPT over the last years
- Challenges and opportunities for EACPT and Clinical Pharmacology
- Welcome talks from chair of the congress

**15:00 to 16:00      PLENARY SESSION**

**Room Meridian      *Chairs:*** Tabassome Simon, Gonzalo Calvo

***Speaker:***

**Adverse drug reactions – state of the art in 2017**

June Raine, *Medicines and Healthcare Products Regulatory Agency, European Medicines Agency, UK*

**16:00 to 17:00**

**Poster Area**

**COFFEE BREAK AND GUIDED POSTER SESSION 1**

**17:00 to 18:00**

**Room Meridian**

**LIFETIME ACHIEVEMENT AWARD**

***Chairs:*** Tabassome Simon, Ylva Böttiger

***Speaker:***

**Steps towards safe and predictable drug treatment - picks from five decades**

Pertti J. Neuvonen, *University of Helsinki, Finland*

**18:00**

**Exhibition Area**

**WELCOME COCKTAIL**

# Sunday, 25 June

8:00 to 9:00  
Room Meridian

## ORAL COMMUNICATIONS 1

**Chairs:** Jan Strojil, Caroline Samer

### **Gene expression of anaesthetic and analgesic drug receptors is associated with clinical metastatic spread in breast cancer**

Cara Connolly<sup>1,2</sup>, Stephen Madden<sup>3</sup>, Donal Buggy<sup>1,2,4</sup>, Helen Gallagher<sup>1,2</sup>  
*University College Dublin, Ireland*  
*Mater Misericordiae University Hospital, Dublin, Ireland*  
*Royal College of Surgeons in Ireland, Dublin, Ireland*  
*Cleveland Clinic, Ohio, USA*

### **Evolution of dihydropyrimidine dehydrogenase (DPD) diagnostics in a single center in a time-period of seven years**

Bianca Van Den Bosch<sup>1</sup>, Aimée Paulussen<sup>1</sup>, Marc Breuer<sup>1</sup>, Martijn Lindhout<sup>1</sup>, Demis Tserpelis<sup>1</sup>, Anja Steyls<sup>1</sup>, Jörgen Bierau<sup>1</sup>, Marieke Coenen<sup>2</sup>  
*Maastricht University Medical Center+, Maastricht, The Netherlands*  
*Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands*

### **Relationship between infliximab serum concentrations and risk of infections in patients treated for spondyloarthritis**

Theodora Bejan-Angoulvant<sup>1,2</sup>, David Ternant<sup>1,2</sup>, Fadela Daoued<sup>1,2</sup>, Frédéric Médina<sup>1,2</sup>, Louis Bernard<sup>2</sup>, Saloua Mammou<sup>2</sup>, Gilles Painsaud<sup>1,2</sup>, Denis Mulleman<sup>1,2</sup>  
*Université François-Rabelais, Tours, France*  
*CHRU de Tours, Tours, France*

### **The pharmacodynamic effects of Rituximab at very low doses**

Christian Schoergenhofer<sup>1</sup>, Christa Firbas<sup>1</sup>, Ulla Derhaschnig<sup>1</sup>, Robert Mader<sup>1</sup>, Raute Sunder-Plaßmann<sup>1</sup>, Petra Jilma-Stohlawetz<sup>1</sup>, Kalpna Desai<sup>2</sup>, Priya Misra<sup>2</sup>, Ulrich Jäger<sup>1</sup>, Bernd Jilma<sup>1</sup>  
*Medical University of Vienna, Austria*  
*Apotex Inc., Toronto, Canada*

### **Safety and efficacy of the C1S complement inhibitor TNT009 in a first-in-human trial**

Johann Bartko<sup>1</sup>, Ulla Derhaschnig<sup>1</sup>, Jim Gilbert<sup>2</sup>, Sandip Panicker<sup>2</sup>, Shirley D'Sa<sup>3</sup>, Ulrich Jäger<sup>1</sup>, Bernd Jilma<sup>1</sup>  
*Medical University of Vienna, Austria*  
*TrueNorth Therapeutics Inc., South San Francisco, USA*  
*University London College Hospitals, United Kingdom*

8:00 to 9:00  
Room Nadir

## HOW TO SESSION

**How to write a paper**

9:00 to 10:30  
Room Meridian

## NEPHROLOGY

Sunday 25 June

**Chairs:**

Milan Grundmann, *University of Ostrava, Czech Republic*

Teun van Gelder, *Erasmus Medical Center, The Netherlands*

**Speakers:**

**Pharmacotherapy after organ transplantation** (30 min.)

Ondrej Viklicky, *Institute for Clinical and Experimental Medicine, Czech Republic*

**TDM and pharmacogenetics in transplantation: What does the evidence say?** (30 min.)

Teun van Gelder, *Erasmus Medical Center, The Netherlands*

**Effect of CYP3A4\*22, CYP3A5\*3, POR\*28, and PPARA RS4253728 on tacrolimus exposure and neurotoxicity in kidney transplant recipients**

Jean-Baptiste Woillard<sup>1</sup>, Nicolas Picard<sup>1</sup>, Marie Essig<sup>1</sup>, Pierre Merville<sup>2</sup>,  
Caroline Monchaud<sup>1</sup>, Pierre Marquet<sup>1</sup>

*CHU Limoges; Univ Limoges, France*

*CHU Bordeaux, France*

**Choice of renal function estimator may affect adverse outcomes with dabigatran**

Bryan Simpson, David Reith, Natalie Medlicott, Alesha Smith

*University of Otago, New Zealand*

**Factors associated with vancomycin concentration variability in routine clinical care**

Ksenia Zagorodnikova, Maria Kostitcyna, Alla Murzina

*North-Western State Medical University N.A.I.I.Mechnikov, Russia*

**9:00 to 10:30**  
**Room Zenit**

**EDUCATION****Chairs:**

Jan Strojil, *Palacky University Olomouc, Czech Republic*

Simon Maxwell, *University of Edinburgh, UK*

**Speakers:**

**Preparing to prescribe** (30 min.)

Tim Dornan, *Queen's University Belfast, UK*

**EACPT study on assessment and curricula** (20 min.)

David Brinkman, *VU University Medical Center, The Netherlands*

**Academic detailing in Norway – caring for GPs where they are**

Roar Dyrkorn, Harald Langaas

*Dept. For Clinical Pharmacology, RELIS, Norway*

**Learning by donning in the student-run pharmacovigilance programme**

Tim Schutte<sup>1,2</sup>, Jelle Tichelaar<sup>1,2</sup>, Michael Reumertman<sup>1,2</sup>, Rike van Eekeren<sup>3,4</sup>,

Lean Rolfes<sup>3,4</sup>, Eugene van Puijenbroek<sup>3,4</sup>, Milan Richir<sup>1,2</sup>, Michiel van

Agtmael<sup>1,2</sup>

*VU University Medical Center, Amsterdam, The Netherlands*  
*RECIPE, Amsterdam, the Netherlands*  
*The Netherlands Pharmacovigilance Centre Lareb (Lareb), 's Hertogenbosch, the Netherlands*  
*University of Groningen, The Netherlands*

**Psychological insuline resistance. Descriptive observational study in 123 patients with Type 2 diabetes mellitus not taking insulin in Paris area, France**

Stephane Mouly, Jean-Francois Bergmann, Pierre-Jean Guillausseau  
*AP-HP-Hopital Lariboisière-University of Paris Diderot, France*

**A multifaceted intervention to improve guideline adherence among prescribing physicians at surgical wards**

Jacqueline Bos<sup>1</sup>, Stephanie Natsch<sup>2</sup>, Patricia van den Bemt<sup>3</sup>, Hans Pot<sup>4</sup>,  
Elsbeth Nagtegaal<sup>4</sup>, Andre Wieringa<sup>5</sup>, Gert Jan van der Wilt<sup>2</sup>, Peter de Smet<sup>2</sup>,  
Cornelis Kramers<sup>1,2</sup>

*Canisius Wilhelmina Hospital, Nijmegen, The Netherlands*  
*Radboud University Medical Center, Nijmegen, The Netherlands*  
*Erasmus University Medical Center, Rotterdam, The Netherlands*  
*Meander Medical Centre, Amersfoort, The Netherlands*  
*Isala Hospital, Zwolle, The Netherlands*

**9:00 to 10:30**  
**Room Nadir**

**REGULATORY**

***Chairs:***

Regina Demlova, *Masaryk Univerzity, Czech Republic*  
Caridad Pontes, *Autonomous University of Barcelona, Spain*

***Speakers:***

**Integration of pharmacogenomics from regulatory perspective (30 min.)**  
Ondrej Slanar, *Charles University, Czech Republic*

**Actual value of subgroups analyses to support regulatory applications (30 min.)**

Julia Carolin Stingl, *University of Bonn, Germany*

**Comparative analysis of regulatory systems for expanded access to investigational drugs in three countries: The Netherlands, Turkey and the United States of America**

Nikkie Aarts, Eline M. Bunnik, Suzanne van de Vathorst  
*Erasmus MC - University Rotterdam, The Netherlands*

**Clinical pharmacology and implementation of the EU clinical trials regulation in Slovakia. Roles and responsibilities taken**

Jozef Glasa, Helena Glasova  
*Slovak Medical University in Bratislava, Slovakia*  
*Slovak Society of Clinical Pharmacology, Slovakia*

**Variability of clinical chemistry parameters in healthy volunteers and overview of Bayer in-house Phase I trials from 2000-2013**

Georg Wensing, Michael Böttcher  
*Bayer AG, Germany*

**10:30 to 11:00**  
**Exhibition Area**

**COFFEE BREAK**

**11:00 to 12:30**  
**Room Meridian**

**EPHAR/EACPT SESSION**

**New therapeutic approaches, from bench to bedside**

***Chairs:***

Gerard Rongen, *Radboud University Medical Center, The Netherlands*  
Thomas Griesbacher, *Medical University of Graz, Austria*

***Speakers:***

**The first molecule interacting with a host protein for the inhibition of multiple viruses** (20 min.)

Maurizio Botta, *University of Siena, Italy*

**Gene therapy for heart failure** (20 min.)

Jean-Sebastien Hulot, *ICAN Paris, France*

**The challenges of cell therapy control for safe, EU-approved Advanced Therapy Medicinal Products** (20 min.)

Graziella Pellegrini, *University of Modena and Reggio Emilia, Italy*

**TDM as a tool for novel targeted anticancer therapy** (20 min.)

Thierry Buclin, *University Hospital Center of the Canton de Vaud, Switzerland*

**Investigation of signalling pathways underlying hypoxic stress in IPS-derived, beating human cardiomyocytes**

Aisling Williams<sup>1</sup>, Katie O'Sullivan<sup>2,3</sup>, Cathal Tobin-O'Brien<sup>1</sup>, Lauren MacDonagh<sup>1</sup>, Eamon Breen<sup>1</sup>, Donal Buggy<sup>1,2,3,4</sup>, John Hurley<sup>3</sup>, Helen Gallagher<sup>1,3</sup>

*University College Dublin, Ireland*

*Mater Private Hospital, Dublin, Ireland*

*Mater Misericordiae University Hospital, Dublin, Ireland*

*Cleveland Clinic, Ohio, USA*

**11:00 to 12:30**  
**Room Zenit**

**EDUCATION**

***BPS block***

***Chair:***

Simon Maxwell, *University of Edinburgh, UK*

***Speakers:***

**Prescribing safety assessment: Ensuring that new graduates are competent to prescribe and supervise the use of medicines in modern healthcare** (20 min.)

Simon Maxwell, *University of Edinburgh, UK*

**Swiss assessment for clinical pharmacology specialists** (20 min.)  
Caroline Samer, *Geneva University Hospitals, Switzerland*

**Teaching Resource Centre: A leading resource for students learning about the clinical pharmacology of commonly used drugs** (20 min.)  
Robert Rissmann, *Leiden University, Netherlands*

**Developing a training environment to introduce students to the use of Electronic Patient Records and ePrescribing** (30 min.)  
Sarah Pontefract, *University of Birmingham, UK*  
Kurt Wilson, *University of Manchester Medical School, UK*

**11:00 to 12:30**  
**Room Nadir**

**PHARMACOVIGILANCE**

***Chairs:***

Karel Urbanek, *Palacky University Olomouc, Czech Republic*  
Gonzalo Calvo, *EACPT, Spain*

***Speakers:***

**Risk minimisation measures: A critical review of their effectiveness** (30 min.)  
Dolores Montero, *Spanish Medicines Agency, Spain*

**Adverse drug reactions in the elderly** (15 min.)  
Martin Wawruch, *Comenius University Bratislava, Slovakia*

**Adverse drug reactions in children** (15 min.)  
Petra Matalova, *Palacky University Olomouc, Czech Republic*

**Safety profile of intravitreal anti-VEGF drugs: An analysis of the Italian spontaneous reporting system**  
Paola Maria Cutroneo<sup>1</sup>, Claudia Giardina<sup>1</sup>, Valentina Ientile<sup>1</sup>, Simona Potenza<sup>2</sup>, Laura Sottosanti<sup>2</sup>, Carmen Ferrajolo<sup>3</sup>, Costantino Trombetta<sup>1</sup>, Gianluca Trifirò<sup>1</sup>  
*University of Messina, Italy*  
*Italian Medicines Agency, Rome, Italy*  
*University of Campania, Naples, Italy*

**Opinions of national competent authorities regarding patient reporting of adverse drug reactions**  
Cristiano Matos<sup>1</sup>, Linda Härmak<sup>2</sup>, Florence van Hunsel<sup>2</sup>  
*University of Seville, Spain*  
*Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands*

**Admission to emergency room during direct oral anticoagulation therapy: Observational study from 2012 to 2016 in French hospital**  
Johana Béné<sup>1</sup>, Alain-Eric Dubart<sup>2</sup>, Catherine Senis<sup>2</sup>, Régis Bordet<sup>1</sup>, Sophie Gautier<sup>1</sup>  
*CHU Lille, Univ.Lille 2, Inserm, Centre Régional de Pharmacovigilance du Nord- Lille, France*

*Centre Hospitalier de Béthune, France*

**12:30 to 14:00**  
**Poster Area**

**LUNCH (Exhibition Area) – GUIDED POSTER SESSION 2**

**14:00 to 15:30**  
**Room Meridian**

**PSYCHIATRY**

***Chairs:***

Milan Grundmann, *University of Ostrava, Czech Republic*  
Eduardo Spina, *University of Messina, Italy*

***Speakers:***

**Novel treatment options in depression and psychosis** (30 min.)  
Eva Ceskova, *Masaryk University, Czech Republic*

**Personalized pharmacotherapy in psychiatry** (30 min.)  
Christoph Hiemke, *University Mainz, Germany*

**Cannabis exposure in young children: Increasing rate of hospitalisation in France in the recent years**

Maryse Lapeyre-Mestre<sup>1,2,3</sup>, Emilie Chauvin<sup>1</sup>, Emilie Jouanjus<sup>1,2,3</sup>, Vanessa Pauly<sup>4</sup>, Margaux Laforie<sup>1</sup>, Anne Roussin<sup>1,2,3</sup>  
*Centre Hospitalier Universitaire de Toulouse, France*  
*Université de Toulouse, France*  
*UMR Inserm 1027, France*  
*Assistance Publique des Hôpitaux de Marseille, France*

**Pharmacodynamic and pharmacokinetic interaction between alcohol and energy drinks**

Clara Pérez-Mañá<sup>1,2</sup>, Julian Mateus<sup>1,2</sup>, Patricia Díaz<sup>1</sup>, Adriana Baggerman<sup>3</sup>, Esther Menoyo<sup>1</sup>, Marta Pérez<sup>1</sup>, Soraya Martín<sup>1</sup>, Mitona Pujadas<sup>1</sup>, Francina Fonseca<sup>1,4</sup>, Rafael de la Torre<sup>1,5</sup>  
*IMIM-Hospital Del Mar Medical Research Institute, Barcelona, Spain*  
*Universitat Autònoma de Barcelona-UAB, Spain*  
*Universitat de Barcelona-UB, Spain*  
*Institut de Neuropsiquiatria i Addiccions (INAD), Barcelona, Spain*  
*Universitat Pompeu Fabra-UPF, Barcelona, Spain*

**Insight gained from genome-wide interaction and enrichment analysis on weight gain during citalopram treatment**

Henrik Corfitsen<sup>1,2</sup>, Antonio Drago<sup>2</sup>  
*Aarhus University, Denmark*  
*Psychiatric Research Unit, Herning, Denmark*

**14:00 to 15:30**  
**Room Zenit**

**SPECIAL POPULATIONS**

***Chairs:***

Ivana Kacirova, *University of Ostrava, Czech Republic*  
Gerard Rongen, *Radboud University Medical Center, The Netherlands*

***Speakers:***

**Sunday 25 June**



**Risk of malformations with antiepileptic drugs (20 min.)**

Dina Battino, *IRCCS Milan, Italy*

**Importance of TDM during pregnancy and breastfeeding (20 min.)**

Ivana Kacirova, *University of Ostrava, Czech Republic*

**Pharmacotherapeutic consequences of (morbid) obesity (20 min.)**

Catherijne Knibbe, *St. Antonius Hospital Nieuwegein, The Netherlands*

**Teratogenic risk of macrolides during the first trimester of pregnancy: A study with two complementary approaches within the EFEMERIS database**

Thuc Lê Nguyen, Mélanie Araujo, Caroline Hurault-Delarue, Isabelle Lacroix, Christine Damase-Michel, Agnès Sommet  
*UMR 1027, University Hospital, University Toulouse 3, France*

**Risk of major congenital malformations after first trimester exposure to topical azoles**

Reut Rotem<sup>1</sup>, Boris Fishman<sup>1</sup>, Gidi Koren<sup>1,2</sup>, Sharon Daniel<sup>1,3</sup>, Eitan Lunenfeld<sup>3</sup>, Amalia Levy<sup>1</sup>

*Ben-Gurion University of The Negev, Israel*

*MAccabi Health Services, Israel*

*Soroka Medical Center, Beer-Sheva, Israel*

**Once-daily aminoglycosides dosing regimen in paediatric cystic fibrosis (CF) patients: A single centre outcomes evaluation**

Hundie Tesfaye, Blanka Jedlickova, Richard Prusa, Jana Bartosova, Veronika Skalicka, Vendula Martinù, Vaclav Koucky, Tereza Dousova  
*University Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic*

**14:00 to 15:30**

**Room Nadir**

**PHARMACOKINETICS**

**Advances in pharmacokinetics: Towards optimised drug treatments**

***Chairs:***

Jaroslav Chladek, *Charles University, Czech Republic*

Janne Backman, *University of Helsinki, Finland*

***Speakers:***

**Recent advances in developmental pharmacokinetics in children (20 min.)**

Saskia de Wildt, *Radboud University, The Netherlands*

**Complex drug-drug interactions: Mechanisms and clinical relevance (20 min.)**

Janne Backman, *University of Helsinki, Finland*

**Population modelling in haemophilia and potential usage in the clinic (20 min.)**

Siv Jönsson, *Uppsala University, Sweden*

**Hepatic disposition of [11C]erlotinib at micro- and therapeutic doses assessed with pet imaging**

Martin Bauer<sup>1</sup>, Akihiro Matsuda<sup>1</sup>, Beatrix Wulkersdorfer<sup>1</sup>, Cecile Philippe<sup>1</sup>, Lukas Nics<sup>1</sup>, Eva-Maria Klebermass<sup>1</sup>, Johann Stanek<sup>1</sup>, Wolfgang Wadsak<sup>1,2</sup>, Marcus Hacker<sup>1</sup>, Markus Zeitlinger<sup>1</sup>

*Medical University of Vienna, Austria*

*Centre for Biomarker Research in Medicine - CBmed GmbH, Graz, Austria*

*AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria*

**Characterization of absorption, metabolism, and elimination of Niraparib, an investigational poly (ADP-ribose) polymerase inhibitor, in cancer patients**

Zhi-Yi Zhang<sup>1</sup>, Vikram Kansra<sup>1</sup>, Lotte van Andel<sup>2</sup>, Matthijs Tibben<sup>2</sup>, Hilde Rosing<sup>2</sup>, Sharon Lu<sup>1</sup>, Shefali Agarwal<sup>1</sup>, Lorraine Hughes<sup>1</sup>, Jan H. M. Schellens<sup>3,4</sup>, Jos H. Beijnen<sup>2,4</sup>

*TESARO Inc, Waltham, USA*

*Antoni van Leeuwenhoek/The Netherlands Cancer Institute and MC*

*Slotervaart, Amsterdam, The Netherlands*

*The Netherlands Cancer Institute, Amsterdam, The Netherlands*

*Utrecht University, The Netherlands*

**Pharmacokinetics and pharmacodynamics of Elobixibat, a novel ileal bile acid transporter inhibitor**

Yuji Kumagai<sup>1</sup>, Hideki Amano<sup>1</sup>, Yoshinobu Sasaki<sup>1</sup>, Chie Nakagawa<sup>1</sup>, Mika Maeda<sup>1</sup>, Ichiro Oikawa<sup>2</sup>, Hidetoshi Furuie<sup>3</sup>

*Kitasato University Hospital, Kanagawa, Japan*

*EA Pharma Co., Ltd., Tokyo, Japan*

*Osaka Pharmacology Clinical Research Hospital, Japan*

**15:30 to 16:00**  
**Exhibition Area**

**COFFEE BREAK**

**16:00 to 17:00**  
**Room Meridian**

**ORAL COMMUNICATIONS 2**

**Chairs:** Gerard Rongen, Dinko Vitezic

**What is the current knowledge about the cardiovascular risk for users of cannabis-based products? A systematic review**

Emilie Jouanjus<sup>1,2</sup>, Valentin Raymond<sup>2</sup>, Maryse Lapeyre-Mestre<sup>1,2</sup>, Valérie Wolff<sup>3</sup>

*Centre Hospitalier Universitaire, Toulouse, France*

*Inserm UMR 1027, Université Toulouse III, Toulouse, France*

*Centre Hospitalier Régional Universitaire, Strasbourg, France*

**Multimorbidity, guidelines and polypharmacy**

Matthew Doogue<sup>1,2</sup>, Annabelle McGowan<sup>1,2</sup>, Murray Barclay<sup>1,2</sup>, David Jardine<sup>1,2</sup>

*University of Otago, New Zealand*

*Canterbury District Health Board, New Zealand*

**Transition study of biosimilar infliximab in patients with inflammatory bowel disease**

Niels Boone, Limmie Lui, Marielle Romberg, Laurence Duijsens, Hugo van der Kuy, Rob Janknegt, Ad van Bodegraven  
*Zuyderland Medical Center, The Netherlands*

**Effect of high dose acetaminophen on liver function tests in healthy subjects**

Yuji Kumagai<sup>1,2</sup>, Ildae Song<sup>1</sup>, Mika Maeda<sup>1,2</sup>, Rieko Tanaka<sup>1</sup>, Yasutoshi Sakamoto<sup>1</sup>, Masako Aso<sup>2</sup>, Yoshiro Saito<sup>3</sup>, Kyoko Maekawa<sup>3</sup>, Tomoe Fujita<sup>1,2</sup>  
*Kitasato University, Kanagawa, Japan*  
*Kitasato University Hospital, Kanagawa, Japan*  
*National Institute of Health Sciences, Tokyo, Japan*

**Drug-induced acute pancreatitis: A four-year single-centre experience**

Karel Urbánek, Kateřina Schillerová, Ondřej Krystyník, Jaromíra Gajdová  
*Palacký University, Olomouc, Czech Republic*

**Sex differences in spontaneous reports on adverse drug events for antihypertensive drugs**

Diana Rydberg<sup>1,2</sup>, Stefan Mejyr<sup>1,2</sup>, Desirée Loikas<sup>2,3</sup>, Karin Schenck-Gustafsson<sup>1,2</sup>, Mia von Euler<sup>1,2</sup>, Rickard Malmström<sup>1,2</sup>  
*Karolinska University Hospital, Stockholm, Sweden*  
*Karolinska Institutet, Stockholm, Sweden*  
*Public Healthcare Services Committee, Stockholm County Council, Sweden*

**16:00 to 17:00**  
**Room Nadir**

**ORAL COMMUNICATIONS 3**

**Chairs:** Tabassome Simon, Matthias Schwab

**Investigating real-world Clopidogrel pharmacogenetics in stroke using a bioresource linked to electronic medical records**

Aleksi Tornio, Robert Flynn, Steve Morant, Elena Velten, Colin N.A. Palmer, Thomas M. MacDonald, Alex S.F. Doney  
*University of Dundee, United Kingdom*

**Effects of carboxylesterase 1 genetic variants on its gene expression, and Clopidogrel pharmacokinetics and antiplatelet effects**

Mikko Neuvonen<sup>1</sup>, Katriina Tarkiainen<sup>1</sup>, Aleksi Tornio<sup>1</sup>, Päivi Hirvensalo<sup>1</sup>, Matti Itkonen<sup>1</sup>, Mikko Holmberg<sup>1</sup>, Ville Männistö<sup>3</sup>, Jussi Pihlajamäki<sup>2,3</sup>, Janne Backman<sup>1</sup>, Mikko Niemi<sup>1</sup>  
*University of Helsinki and Helsinki University Hospital, Finland*  
*Kuopio University Hospital, Finland*  
*University of Eastern Finland, Kuopio, Finland*

**Pharmacogenetic algorithm for acenocoumarol dosing improve anticoagulation control: A multicenter randomized clinical trial**

Hoi Tong<sup>1</sup>, Alberto M. Borobia<sup>1,2</sup>, María Rodríguez Dávila<sup>1</sup>, Nuria Ruiz-Giménez<sup>3</sup>, Manuel González Viñolis<sup>1</sup>, Olga Madridano<sup>4</sup>, Ana López Parra<sup>5</sup>, Pilar Llamas Sillero<sup>6</sup>, Jesús Frías<sup>1,2</sup>, Antonio Carcas Sansuán<sup>1,2</sup>  
*La Paz University Hospital, IdiPAZ, Madrid, Spain*  
*School of Medicine. Autonomous University de Madrid, Spain*  
*La Princesa University Hospital, Madrid, Spain*  
*Infanta Sofía University Hospital, Madrid, Spain*

*Complutense University of Madrid, Spain  
Fundación Jiménez Díaz University Hospital, Madrid, Spain*

**Innate immune genetic markers predict postoperative morphine consumption in an ethnicity-dependent manner**

Andrew Somogyi<sup>1</sup>, Daniel Barratt<sup>1</sup>, Ene-Choo Tan<sup>2</sup>, Alex Sia<sup>2</sup>  
*University of Adelaide, Adelaide Medical School, Australia  
KK Women's and Children's Hospital, Singapore*

**17:00 to 18:30  
Room Meridian**

**NEUROLOGY**

***Chairs:***

Milan Grundmann, *University of Ostrava, Czech Republic*  
Marie Besson, *Geneva University Hospitals, Switzerland*

***Speakers:***

**Neurological side effects of drugs** (20 min.)  
Regis Bordet, *University of Lille, France*

**Epilepsy treatment introduction** (20 min.)  
Vilem Novak, *University Hospital Ostrava, Czech Republic*

**Improving the safety of new antiepileptic agents by individualized dosing** (30 min.)  
Anders Helldén, *Karolinska Institutet, Sweden, Sweden*

**GABAA subtypes-selective modulation: A novel mechanism-based approach to the treatment of neuropathic pain**  
Alain Matthey<sup>1</sup>, Youssef Daali<sup>1</sup>, William Ralvenius<sup>2</sup>, Hanns Ulrich Zeilhofer<sup>2,3</sup>,  
Jules Desmeules<sup>1</sup>, Marie Besson<sup>1</sup>  
*Geneva University Hospitals, Switzerland  
University of Zurich, Switzerland  
Swiss Federal Institute of Technology (ETH) Zurich, Switzerland*

**Mortality related to benzodiazepines or other psychotropic drugs in patients with cancer**  
Berangere Baricault<sup>1,2</sup>, Aurore Palmaro<sup>1,2</sup>, Maryse Lapeyre-Mestre<sup>1,2</sup>  
*Universite de Toulouse, France  
UMR INSERM 1027, France*

**17:00 to 18:30  
Room Zenit**

**e-HEALTH**

***Chairs:***

Jan Strojil, *Palacky University Olomouc, Czech Republic*  
Ylva Böttiger, *Linköping University, Sweden*

***Speakers:***

**Digital health technologies in hospital medicines management** (30 min.)  
Jamie Coleman, *University of Birmingham, UK*

**Decision support systems for medicines – paths for the future** (30 min.)

**Sunday 25 June**

Birgit Eiermann, *Karolinska Institutet, Sweden*

**Dabigatran exposure and outcomes: A PK/PD/PV study**

David Reith, Bryan Simpson, Natalie Medlicott, Aesha Smith  
*University of Otago, New Zealand*

**Do electronic prescribing systems in English hospitals support antimicrobial stewardship? An analysis of 'start smart – then focus' functionality**

Imun Madar<sup>1</sup>, Jamie Coleman<sup>1</sup>, Ann Slee<sup>2</sup>, Sarah Pontefract<sup>1</sup>  
*University of Birmingham, United Kingdom*  
*NHS England, London, United Kingdom*

**Utilisation of New Zealand primary care electronic data to guide clinical decision support system design—a retrospective cohort for Dabigatran**

Bryan Simpson, David Reith, Natalie Medlicott, Alesha Smith  
*University of Otago, New Zealand*

**17:00 to 18:30**  
**Room Nadir**

**BIOMARKERS AND PRECISION MEDICINE**

***Chairs:***

Jitka Patockova, *Medical and Radiology Clinic Prague, Czech Republic*  
Matthias Schwab, *Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Germany*

***Speakers:***

**The U-PGx Project: Implementation of pharmacogenomics in Europe** (30 min.)

Henk-Jan Guchelaar, *Leiden University Medical Center, The Netherlands*

**Predictive markers for prognosis and drug therapy in renal cancer** (30 min.)

Matthias Schwab, *Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Germany*

**Drug transporter variants as predictors of cancer chemotherapy-induced toxicity** (30 min.)

Donald Singer, *EACPT, UK*

**18:30 to 19:30**  
**Room Nadir**

**EACPT ASSEMBLY**

# Monday, 26 June

8:00 to 9:00  
Room Meridian

## ORAL COMMUNICATIONS 4

**Chairs:** Donald Singer, Marie Besson

### **Medicines communications using digital media: Findings from a survey of member organisations of the European medicines agency's patients and consumers and health professionals working parties (PCWP and HCPWP)**

Donald Singer<sup>1</sup>, Ivana Silva<sup>2</sup>, Maria Mavris<sup>2</sup>  
*EACPT*  
*EMA London, UK*

### **Investigator initiated clinical trials: Portuguese case**

Emília Monteiro, Catarina Madeira  
*Portuguese Clinical Research Infrastructure Network (PtCRIN), Portugal*  
*European Clinical Research Infrastructure Network (ECRIN), Portugal*  
*Nova Medical School, Portugal*

### **Over exposure to Efavirenz plasma concentrations among Beninese HIV patients treated by a 600 mg daily dose**

Aurel Constant Allabi<sup>1</sup>, Mikal Kiki<sup>1</sup>, Marcel Zannou<sup>1</sup>, Jean-Claude Alvarez<sup>2</sup>  
*Université D'Abomey-Calavi/ FSS/Unité de Pharmacologie, Benin*  
*Fac de Médecine PIFO, INSERM U-1173 CHU Garches, AP-HP, Benin*

### **Does patient health empowerment go hand in hand with privacy empowerment?**

Leticia Pereira, David García, Silvia Fernández, Neus Riba, María Jesús Bertran  
*Hospital Clínic of Barcelona, Spain*

### **Public knowledge, beliefs, and behavior regarding the use of antibiotics in Serbia**

Olga Horvat, Tinde Halgato, Ana Tomas, Milica Paut, Zdenko Tomić, Ana Sabo  
*University of Novi Sad, Serbia*

### **Low dose vs. standard dose adjuvant olanzapine in chemotherapy induced nausea and vomiting: A prospective, randomized, double blinded, controlled study**

Sandip Mukhopadhyay, Premnath Dutta, Biswamit Bhattacharya, Sanatan Banerjee, Supreeti Biswas, Basabdatta Samanta-Mukhopadhyay  
*Burdwan Medical College, India*

8:00 to 9:00  
Room Nadir

## HOW TO SESSION

**How to review a paper**

9:00 to 10:30  
Room Meridian

## ONCOLOGY

**Chairs:**

Monday 26 June

Regina Demlova, *Masaryk University, Czech Republic*  
Caroline Samer, *Geneva University Hospitals, Switzerland*

**Speakers:**

**Immunotherapy of cancer** (20 min.)

Ana Arance, *Hospital Clinic Barcelona, Spain*

**Are the host-dependent variables the forgotten key to personalised medicine?** (20 min.)

Regina Demlova, *Masaryk University, Czech Republic*

**Benefits and challenges of fast-track drug approval in oncology** (20 min.)

Curt Peterson, *Linköping University, Sweden*

**Computational Horizons in Cancer (CHIC)** (20 min.)

Georgios Stamatakis, *National Technical University of Athens, Greece*  
(on behalf of the CHIC consortium)

**9:00 to 10:30**  
**Room Zenit**

**SYMPOSIUM OF SFPT**

**The Rennes disaster: Lessons to be drawn**

**Chairs:**

Francesco Salvo, *University Hospital Bordeaux, France*

Gonzalo Calvo, *EACPT, Spain*

**Speakers:**

**The Rennes disaster – Lessons to learn** (35 min.)

Bernard Bégaud, *French Drug Agency, France*

**The measures of French regulatory agency for clinical trials conduction after the Rennes disaster** (15 min.)

Anne Gimbert, *REVIIES, France*

**Practical implication of the last EMA regulation for clinical trials** (20 min.)

Gonzalo Calvo, *EACPT, Spain*

**Is there a need for independent investigation of accidents in human clinical research?** (20 min.)

Brian Edwards, *ISoP, UK*

**9:00 to 10:30**  
**Room Nadir**

**GLOBAL HEALTH**

**Access to medicines (ensuring the supply chain for access to safe and effective medicines)**

**Chairs:**

Jozef Glasa, *Slovak Medical University in Bratislava, Slovakia*

Donald Singer, *EACPT, UK*

**Speakers:**

**Monday 26 June**

**Securing the supply chain of medicines: Whose responsibility?** (20 min.)  
Mike Isles, *EAASM, UK*

**Challenges and solutions for policy makers for access to medicines** (20 min.)  
Jozef Glasa, *Slovak Medical University in Bratislava, Slovakia*

**Fight against falsified medicines: Serbia's example and coordinated actions at EDQM level through the Medicrime Convention** (20 min.)  
Pavle Zelic, *Medicines and Medical Devices Agency, Serbia*

**Discussion Panel**  
Jozef Glasa, Donald Singer, Mike Isles, Pavle Zelic, June Raine

**10:30 to 11:00**  
**Exhibition Area**

**COFFEE BREAK**

**11:00 to 12:30**  
**Room Meridian**

**PHARMACOGENOMICS AND EPIGENOMICS**  
*Joint session with IUPHAR*

***Chairs:***

Guilherme Suarez-Kurtz, *Cancer Treatment Center Rio de Janeiro, Brazil*  
Ingolf Cascorbi, *University of Kiel, Germany*

***Speakers:***

**Genetic and epigenetic mechanisms of TKI resistance** (25 min.)  
Ingolf Cascorbi, *University of Kiel, Germany*

**Pharmacogenomics of colorectal cancer: From discovery to clinical implementation and back** (25 min.)  
Erika Cecchin, *National Cancer Institute Aviano, Italy*

**ADME gene regulation through miRNA – role of inflammation** (25 min.)  
Ulrich Zanger, *IKP Stuttgart, Germany*

**Pharmacogenetics of chemotherapy response in osteosarcoma: A genetic variant in SLC7A8 is associated with progressive disease**  
Marieke Coenen<sup>1</sup>, Hanneke Vos<sup>1</sup>, Johanne Groothuismink<sup>1</sup>, Hans Gelderblom<sup>2</sup>, Henk-Jan Guchelaar<sup>2</sup>, Maroeska te Loo<sup>1</sup>, Genetics of Osteosarcoma consortium<sup>3</sup>  
*Radboud University Medical Center, The Netherlands*  
*Leiden University Medical Center, The Netherlands*  
W.T.A. van der Graaf, U. Flucke, H.W.B. Schreuder, M.M. Hagleitner, T. van der Straaten, E.S.J.M. de Bont, L.C.M. Kremer, J. Bras, H. Caron, R. Windsor, J. Whelan, A. Patiño-García, A. González-Neira, G. McCowage, S. Nagabushan, D. Catchpoole, F.N. van Leeuwen

**11:00 to 12:30**  
**Room Zenit**

**EACPT MEETS THE ASIAN SOCIETIES**  
*Joint session with KSCPT*

**Monday 26 June**



**Chairs:**

Tabassome Simon, *EACPT, France*  
Jae Gook Shin, *KSCPT, Rep. of Korea*

**Speakers:**

**Education and training of clinical pharmacology in Korea** (20 min.)  
Kyun-Seop Bae, *Asan Medical Center, Univ. of Ulsan, Rep. of Korea*

**Biologic treatment of rheumatoid arthritis treatment, current status and future perspectives** (20 min.)

Karel Pavelka, *Institute of Rheumatology Prague, Czech Republic*

**Pharmacometrics in academia: Role for clinical researches and dissemination to industry in Korea** (20 min.)

Dong-Seok Yim, *The Catholic University of Korea, Rep. of Korea*

**Biological therapy for high-prevalence diseases** (20 min.)

Caridad Pontes, *Autonomous University of Barcelona, Spain*

**11:00 to 12:30**  
**Room Nadir**

**ANTI-INFECTIVES****Chairs:**

Karel Urbanek, *Palacky University Olomouc, Czech Republic*  
Gerard Rongen, *Radboud University Medical Center, The Netherlands*

**Speakers:**

**Advances and challenges in vaccine therapy** (30 min.)  
Ronald de Groot, *Radboud University Medical Center, The Netherlands*

**Antibiotic utilization and bacterial resistance** (30 min.)

Milan Kolar, *Palacky University Olomouc, Czech Republic*

**Effectiveness of nurse-driven HIV screening targeting key populations in emergency departments in metropolitan Paris: The ANRS DICI-VIH cluster-randomized two-period crossover trial**

Judith Leblanc<sup>1</sup>, Carole Jegou<sup>2</sup>, Nadia Fossoux<sup>3</sup>, Cécile Lancien<sup>4</sup>, Théophile Bastide<sup>5</sup>, Rachel Verbrugghe<sup>6</sup>, Cécile Jauneau<sup>7</sup>, Hélène Piquet<sup>8</sup>, Anne-Claude Crémieux<sup>9</sup>, Tabassome Simon<sup>10</sup>

*Groupe Hospitalier des Hôpitaux Universitaires Est Parisien/ Université Paris Saclay-Université Versailles St Quentin, Garches, France*

*Hôpital Avicenne, Bobigny, France*

*Hôpital Bicêtre, Le Kremlin-Bicêtre, France*

*Centre Hospitalier de Saint Denis, Hôpital Delafontaine, Saint Denis, France*

*Hôpital Lariboisière, Paris, France*

*Hôpital Tenon, Paris, France*

*Centre Hospitalier de Gonesse, Gonesse, France*

*Hôpital Saint Antoine, Paris, France*

*Hôpital Saint Louis, Paris/ Université Versailles St Quentin, Garches, France*

*Groupe Hospitalier des Hôpitaux Universitaires Est Parisien / Sorbonne Universités, UPMC Univ Paris 06, France*

**Outpatient antibiotic prescriptions with high risk of bacterial resistance in France: A national healthcare insurance database analysis**

Marie-Céline Casaurancq, Manuela Rueter, Bérangère Baricault, Emilie Patras de Campaigno, Mélanie Araujo, Maryse Lapeyre-Mestre, Agnès Sommet  
*University Hospital, University Toulouse 3, France*

**Target-site pharmacokinetics of the echinocandin antifungal anidulafungin in ascites and pleural effusion during critical illness**

René Welte<sup>1</sup>, Ingo Lorenz<sup>1</sup>, Philipp Eller<sup>2</sup>, Michael Joannidis<sup>1</sup>, Romuald Bellmann<sup>1</sup>  
*Medical University of Innsbruck, Austria*  
*Medical University of Graz, Austria*

**12:30 to 14:00** **LUNCH (Exhibition Area) – GUIDED POSTER SESSION 3**  
**Poster Area**

**14:00 to 15:30** **CARDIOVASCULAR**  
**Room Meridian**

***Chairs:***

Otto Mayer, *Charles University, Czech Republic*  
Tabassome Simon, *EACPT, France*

***Speakers:***

**Impact of recent advances in management of dyslipidemia on cardiovascular morbidity and mortality** (30 min.)  
Tomas Stulc, *Charles University, Czech Republic*

**Antidiabetic treatment of T2DM and cardiovascular risk** (30 min.)  
Hana Rosolova, *Charles University, Czech Republic*

**Causes of death in anticoagulated patients with venous thromboembolism**

Antonio Gómez-Outes<sup>1</sup>, Ana-Isabel Terleira-Fernández<sup>2</sup>, Ramón Lecumberri<sup>3</sup>, Gonzalo Calvo-Rojas<sup>4</sup>, M<sup>a</sup>.Luisa Suárez-Gea<sup>1</sup>, Emilio Vargas-Castrillón<sup>2</sup>  
*Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, Spain*  
*Hospital Clínico San Carlos and Universidad Complutense, Madrid, Spain*  
*Clínica Universidad de Navarra, Pamplona, Spain*  
*Hospital Clinic, Barcelona, Spain*

**On demand sildenafil as a treatment of Raynaud's phenomenon: A series of N-of-1 trials**

Matthieu Roustit<sup>1,2,3</sup>, Joris Gai<sup>4,5,6</sup>, Olivier Gaget<sup>3</sup>, Myriam Mouhib<sup>3</sup>, Adrien Lotito<sup>3</sup>, Charles Khouri<sup>3</sup>, Sophie Blaise<sup>2,3</sup>, Christophe Seinturier<sup>3</sup>, Sunita Vohra<sup>7</sup>, Jean-Luc Cracowski<sup>1,2,3</sup>  
*Univ. Grenoble-Alpes, France*  
*Inserm, HP2 UMR 1042, Grenoble, France*  
*CHU Grenoble-Alpes, France*  
*Université de Lyon, France*  
*CNRS, UMR5558, Villeurbanne, France*

*Hospices Civils de Lyon, France*  
*University of Alberta, Edmonton, Canada*

**Modelling of outcome postponement for cardiovascular outcomes in statin trials**

Morten Rix Hansen<sup>1</sup>, Anton Pottegård<sup>1</sup>, Asbjørn Hróbjartsson<sup>2,3</sup>, Per Damkier<sup>1,5</sup>, René dePont Christensen<sup>1</sup>, Jesper Hallas<sup>1,2</sup>  
*Clinical Pharmacology And Pharmacy University of Southern Denmark, Odense, Denmark*  
*Odense University Hospital, Denmark*  
*Center for Evidence-Based Medicine University of Southern Denmark, Denmark*  
*Research unit for general practice, Denmark*  
*Department of Clinical Research, University of Southern Denmark, Denmark*

**14:00 to 15:30**  
**Room Zenit**

**BIG DATA**  
**BPS block**

**Chair:**

Munir Pirmohamed, *University of Liverpool, UK*

**Speakers:**

**Big Data in pharmacoepidemiology** (30 min.)  
Patricia McGettigan, *QMUL London, UK*

**Can we use social media for pharmacovigilance** (30 min.)  
Simon Maskell, *University of Liverpool, UK*

**Use of genomics for drug discovery** (15 min.)  
Matt Nelson, *University of North Carolina, USA*

**Combining genomics and electronic health records data for disease development and drug response** (15 min.)  
Mads Melbye, *University of Copenhagen, Denmark*

**14:00 to 15:30**  
**Room Nadir**

**PHARMACOECONOMICS**

**Chairs:**

Tomas Dolezal, *Institute of Health Economics and Technology Assessment Prague, Czech Republic*  
Dinko Vitezic, *University of Rijeka Medical School, Croatia*

**Speakers:**

**Opportunities and constraints to harmonize pharmacoeconomic methods across European countries** (20 min.)  
Zoltan Kalo, *Eötvös Loránd University, Hungary*

**HTA trends in middle and low income countries – example of CEE region** (20 min.)

Tomas Dolezal, *Institute of Health Economics and Technology Assessment  
Prague, Czech Republic*

**Cost-effectiveness of genotype-guided warfarin dosing in the patients with mechanical heart valve replacement under fee-for-service system**

Dong-Jin Kim<sup>1</sup>, Ho-Sook Kim<sup>1</sup>, Minkyong Oh<sup>1</sup>, Eun-Young Kim<sup>1,2</sup>, Jae-Gook Shin<sup>1,2</sup>

*University College of Medicine, Busan, South Korea*

*University Busan Paik Hospital, Busan, South Korea*

**Discussion** (30 min.)

**15:30 to 16:00**      **COFFEE BREAK**  
**Exhibition Area**

**16:00 to 17:00**      **PLENARY DEBATE**  
**Room Meridian**      **It is difficult to successfully communicate the risk to benefit ratio of medicines to the patient**

**Chairs:** Caridad Pontes, Tabassome Simon

**Speakers:**

**Pro:** Rosa González-Quevedo, *EMA London, UK*

**Con:** Mikael Hoffmann, *The Swedish Society of Medicine, Sweden*

**17:00 to 18:30**      **ORAL COMMUNICATIONS 5**  
**Room Zenit**      **Chairs:** Milan Grundmann, Edoardo Spina

**Effect of ABCB1 inhibition at the blood-brain barrier on brain distribution of the ABCB1 substrate (r)-[11C]verapamil in elderly versus young subjects**

Martin Bauer<sup>1</sup>, Rudolf Karch<sup>1</sup>, Beatrix Wulkersdorfer<sup>1</sup>, Wolfgang Wadsak<sup>1</sup>, Marcus Hacker<sup>1</sup>, Markus Zeitlinger<sup>1</sup>, Oliver Langer<sup>1,2</sup>

*Medical University of Vienna, Austria*

*AIT Austrian Institute of Technology GmbH, Austria*

**Bioequivalence studies of highly variable drugs - an example of Itraconazole**

Viktorija Dragojevic-Simic<sup>1</sup>, Aleksandra Kovacevic<sup>1</sup>, Nemanja Rancic<sup>1</sup>, Vesna Jacevic<sup>1</sup>, Snezana Djordjevic<sup>1</sup>, Vesna Kilibarda<sup>1</sup>, Zoran Segrt<sup>1</sup>, Momir Mikov<sup>2</sup>

*Military Medical Academy, Belgrade, Serbia*

*Institute for Pharmacology, Clinical Pharmacology and Toxicology, Medical Faculty, Novi Sad, Serbia*

**Posaconazole tablets versus posaconazole oral suspension in lung transplant patients: Which consequences on immunosuppressive therapy?**

Elodie Gautier-Veyret<sup>1,2,3</sup>, Sebastien Chanoine<sup>1,3</sup>, Hélène Pluchart<sup>1,3</sup>, Julia Tonini<sup>3</sup>, Xavier Fonrose<sup>3</sup>, Christophe Pison<sup>1,3</sup>, Pierrick Bedouch<sup>1,3</sup>, Françoise Stanke-Labesque<sup>1,2,3</sup>

**Monday 26 June**

*Univ. Grenoble Alpes, HP2, Grenoble, France*  
*INSERM U1042, Grenoble, France*  
*Centre Hospitalier Universitaire des Alpes, Grenoble, France*

**Population pharmacodynamic analysis of effect of three increasing doses of fludrocortisone on phenylephrine-mean arterial pressure dose-response relationship in healthy volunteers**

Karima Hammas<sup>1,2</sup>, Nouredine Hamitouche<sup>1</sup>, Clément Palpacuer<sup>1,2</sup>, Fabrice Lainé<sup>1</sup>, Eric Bellissant<sup>1,2</sup>, Bruno Laviolle<sup>1,2</sup>  
*Inserm, CIC 1414 Clinical Investigation Centre, Rennes, France*  
*Rennes University Hospital, Clinical Pharmacology, Rennes, France*

**Results of the population PK modelling of rtxmb83, a rituximab biosimilar candidate in patients with diffuse large B-cell lymphoma (DLBCL)**

Myrna Candelari<sup>1</sup>, Derlis Gonzalez<sup>2</sup>, Marcia Torresan<sup>3</sup>, Daniel Bar<sup>4</sup>, Amalia Florez<sup>5</sup>, Alexandra Paravisini<sup>5</sup>, Francisco Fernandez<sup>5</sup>, Susana Millan<sup>5</sup>  
*Instituto Nacional de Cancerología, Tlalpan, Sección XVI, Mexico DF, México*  
*Instituto Privado de Hematología E Investigación Clínica (IPHIC), Asunción, Paraguay*  
*Hemocentro da Universidade Estadual de Campinas/ UNICAMP, Campinas, São Paulo, Brazil*  
*Hospital Iturraspe, Santa Fe, Argentina*  
*Mabxience*

**Evidenced based drug-drug interaction alerts in an e-prescribing system**

Matthew Doogue<sup>1,2</sup>, Amanda Crawford<sup>1</sup>, Hayleigh Miller<sup>1</sup>, Philip Drennan<sup>2</sup>, QianYi Chuah<sup>2</sup>, Matthew Strother<sup>1,2</sup>, Paul Chin<sup>1,2</sup>  
*University of Otago, Christchurch, New Zealand*  
*Canterbury District Health Board, New Zealand*

**Is pharmacogenetics of antidepressant-related metabolic genes applicable to clinical reality of recurrent depression?**

Diana Pendicheva<sup>1</sup>, Reni Tzveova<sup>2,3</sup>, Radka Kaneva<sup>2,3</sup>, Ivo Duhlenki<sup>4</sup>  
*Medical University-Pleven, Bulgaria*  
*Molecular Medicine Center, Sofia, Bulgaria*  
*Medical University-Sofia, Bulgaria*  
*Diagnostic Consultation Center II, Pleven, Bulgaria*

**17:00 to 18:30**  
**Room Nadir**

**SYMPOSIUM**

**Therapeutic Drug Monitoring - MS-based approaches at the University Hospital of Vienna**

**Speaker:**

Thomas Stimpfl, Medical University - General Hospital of Vienna, Austria

# Tuesday, 27 June

**9:00 to 10:30**  
**Room Meridian**      **Rational use of drugs in Europe - what can we learn from cross-national comparisons of drug utilization**

A symposium dedicated to the late Ludvík Štika

***Joint session with EuroDURG***

**Chairs:**

Robert Vander Stichele, *EuroDURG, University of Gent, Belgium*

Jiri Vlcek, *Charles University, Czech Republic*

**Speakers:**

**A tribute to a pioneer in Drug Utilization Research: Ludvik Stika** (10 min.)

Ulf Bergman, *Karolinska Institute, Sweden*

**Drug consumption of antibiotics and anticoagulant agents from ecological and longitudinal perspectives – recent possibilities and role of drug consumption studies in the Czech Republic** (25 min.)

Jiri Vlcek, *Charles University, Czech Republic*

Jana Mlada, *SUKL, Czech Republic*

**Lessons from CNC for the appraisal of access to medicines, prescribing, and pharmaceutical policies** (25 min.)

Robert Vander Stichele, *University of Gent, Belgium*

**Five-year antimicrobial susceptibility trends among bacterial isolates from King Faisal Hospital tertiary health-care facility in Kigali, Rwanda**

Donald RJ Singer<sup>1</sup>, Makeda Carroll<sup>2</sup>, Ashok Rangaiahagari<sup>3</sup>, Emmanuel Musabeyezu<sup>4</sup>, Onyema Ogbuagu<sup>5</sup>

*Fellowship of Postgraduate Medicine, London, UK*

*Department of Public Health, Philadelphia, Pennsylvania, USA*

*SMBT Institute of Medical Science and Research Center, Nashik, India*

*King Faisal Hospital, Kigali, Rwanda*

*Yale University School of Medicine, New Haven, Connecticut, USA*

**10:30 to 10:45**  
**Exhibition Area**      **COFFEE BREAK**

**10:45 to 12:00**  
**Room Meridian**      **EACPT scientific award and joint EACPT- EPHAR awards**  
**Lifetime educator and young educator awards**  
**Presentation of winners of EPHAR/EACPT young translational investigation award**

**CLOSING CEREMONY**

**Chairs:** Tabassome Simon, Ylva Böttiger